<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article111</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/CONSENSUS" style="display:block; margin-bottom:10px;">CONSENSUS Original</a></li>
<h2><strong>CONSENSUS</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Enalapril in Severe Congestive Heart Failure". The New England Journal of Medicine. 1987. 316(23):1429-1435. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
<br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes <br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
<br/>
Does the addition of the angiotensin-converting-enzyme inhibitor enalapril to conventional therapy in patients with severe congestive heart failure improve survival and symptoms?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
<br/>
In patients with severe congestive heart failure (NYHA class IV), enalapril reduces mortality and improves symptoms when added to conventional therapy.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
<br/>
The prognosis of severe congestive heart failure is poor, but the utility of angiotensin-converting-enzyme inhibitors (ACE inhibitors) on survival was previously unknown. This landmark randomized controlled trial established that enalapril significantly improved both survival and clinical symptoms in patients with severe heart failure.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
<br/>
Modern guidelines recommend ACE inhibitors as part of standard therapy for heart failure with reduced ejection fraction.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
<br/>
- Multicenter, double-blind, placebo-controlled, parallel-group trial<br/>
- N=253 patients with NYHA class IV heart failure<br/>
- Enalapril (n=127)<br/>
- Placebo (n=126)<br/>
- Follow-up averaged 188 days, up to 20 months<br/>
- Primary endpoint: Crude mortality at six months<br/>
- Secondary endpoints: 12-month and overall mortality during the entire trial period<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
<br/>
Inclusion Criteria<br/>
<br/>
- Severe congestive heart failure (NYHA class IV)<br/>
- History of heart disease with symptoms of dyspnea or fatigue or both, along with signs of fluid retention and no evidence of primary pulmonary disease<br/>
- Enlarged heart size radiologically (more than 600 ml/m² in men or more than 550 ml/m² in women)<br/>
<br/>
Exclusion Criteria<br/>
<br/>
- Acute pulmonary edema, significant valve stenosis, recent myocardial infarction, unstable angina, planned cardiac surgery, right heart failure due to pulmonary disease, serum creatinine above 300 μmol/L<br/>
<br/>
Baseline Characteristics<br/>
<br/>
- Similar clinical characteristics between enalapril and placebo groups<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
<br/>
- Enalapril or placebo started with a dose of 5 mg twice a day in the hospital, increased to 10 mg twice daily after one week as tolerated, and further increased up to 20 mg twice a day<br/>
- Protocol adjusted for high-risk patients to start at 2.5 mg daily<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
<br/>
Primary Outcome<br/>
<br/>
- Six-month mortality was 26% in the enalapril group vs. 44% in the placebo group<br/>
<br/>
Secondary Outcomes<br/>
<br/>
- Mortality at one year and end of the study was reduced by 31% and 27%, respectively, with enalapril<br/>
- Sudden cardiac death incidence was similar between groups<br/>
- Deaths from progression of heart failure reduced by 50% in enalapril group<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
<br/>
- The trial's dosage and administration adjustments may not reflect current practice<br/>
- The study did not provide long-term data on the duration of the beneficial effect or its effects in less severe forms of heart failure<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
<br/>
- Supported by a grant from Merck Sharp and Dohme Research Laboratories<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
<br/>
More detail can be found in the original publication in The New England Journal of Medicine.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
